Performance Food Grの空売り状況は、投資家がPerformance Food Grの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Performance Food Gr (NYSE:PFGC) 株価情報, 空売り情報

PERFORMANCE FOOD GROUP CO

Performance Food Gr

Performance Food Group Co , markets and distributes national and company-branded food and food-related products. The company also specializes in distributing candy, snacks, beverages, cigarettes, other tobacco products, health and beauty care products and other items to vending distributors, box retailers, theaters, convenience stores, drug stores, grocery stores, travel providers, and hospitality providers. The company has three reportable segments: Foodservice, Vistar, and Convenience.

Performance Food Group

Earnings

Equities

News

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

CSCO

GOOGL

HNHPF

LITE

NVDA

PFGC

PTON

８月３日（水）午前８時３０分（米国東部時間）に公表される消費者物価指数（CPI）速報に先駆け、主要指数先物は神経質な値動きを示している。債券利回りは消費者物価指数発表前に低下している。今回の報告が価格圧力の緩和が続いていることを確認した場合、米連邦準備制度理事会（FRB）は利上げを余儀なくされる可能性がある。経済学者やストラテジストは、FRB総裁のジェローム・パウエル氏が今月末に予定されている＜ジャクソンホール・シンポジウム＞で、利上げ見通しについてさらに明確な見解を示すと予想している。

ウォール・ストリート　主要先物指数が反応

Performance Food Group Company Common Stock

Performance Food Group Co

Citigroup analyst Steven Zaccone downgrades RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from Buy to Neutral and lowers the price target from $437 to $200.

Downgrades

Price Target

Analyst Ratings

Citigroup Downgrades RH to Neutral, Lowers Price Target to $200

Citigroup analyst Steven Zaccone downgrades Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) from Buy to Neutral and lowers the price target from $93 to $70.

Citigroup Downgrades Best Buy Co to Neutral, Lowers Price Target to $70

Citigroup analyst Paul Lejuez upgrades Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Neutral to Buy and announces $146 price target.

Upgrades

ROST

Citigroup Upgrades Ross Stores to Buy, Announces $146 Price Target

Citigroup analyst Paul Lejuez upgrades TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) from Neutral to Buy and raises the price target from $128 to $140.

Citigroup Upgrades TJX Companies to Buy, Raises Price Target to $140

Ladenburg Thalmann analyst Christopher Nolan downgrades Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) from Buy to Neutral.

SACH

Ladenburg Thalmann Downgrades Sachem Cap to Neutral

Sonim, through a previously established Special Committee of the Board composed of independent directors, is carefully reviewing and evaluating the proposal in consultation with its legal and financial advisors.&nbsp;
Sonim does not intend to comment further on the matter unless the Special Committee determines that additional disclosure is in the best interest of shareholders.

SONM

Sonim Technologies Confirms Receipt Of Unsolicited Non-binding Proposal From Orbic At $4.00 Per Share In Cash

HC Wainwright &amp; Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) with a Buy and maintains $16 price target.

Reiteration

ACIU

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

NTLA

Intellia Begins Phase 3 Trial for CRISPR Gene Therapy Targeting Rare Nerve Disease

Crescent also appointed Jonathan McNeill, president and chief operating officer; Ellie Im, M.D., chief medical officer; Rick Scalzo, MBA, chief financial officer; and Amy Reilly, chief communications officer.

Management

GLYC

GlycoMimetics Merger-Bound Crescent Appoints Joshua Brumm As CEO

Guidance

Conagra Brands Reaffirms FY25 Organic Net Sales Decline of 2%; Adj EPS of $2.35 Vs. $2.35 Est.

Macro Economic Events

March Challenger Job Cuts 275,240 Up 60% Vs February

Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.

IXHL

Incannex Completes Phase 2 Enrollment for Sleep Apnea Drug Trial Targeting Better Rest

RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares are trading lower premarket on Thursday.
On Wednesday, the company disclosed first-quarter preliminary <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43956479/rxsight-inc-reports-fourth-quarter-and-full-year-2024-financial-results-reaffirms-2025-guidance" rel="noreferrer noopener">results and revised its FY25 outlook</a>.
The company sees first-quarter revenue of around $37.9 million, up 28% year over year and down 6% quarter over quarter, and below the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $40.14 million</a>.
RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume.
Also, the company anticipates the sale of 73 Light Delivery Devices (LDDs), increasing the installed base to 1,044 LDDs by March 31, 2025, marking a 43% Y/Y growth.
Revised FY25 Outlook: The company lowered the revenue outlook to $160.0 million &#8211; $175.0 million (vs. consensus of $188.9 million) from $185.0 million &#8211; $197.0 million earlier.
Also, RxSight curtailed the operating expenses outlook to $150 million &#8211; $160 million from $165 million &#8211; $170 million prior.
Ron Kurtz, Chief Executive Officer and President of RxSight, said, &#8220;Given RxSight&#8217;s more significant installed base of surgeons and practices, we now must navigate headwinds affecting the overall premium IOL market and broader economy that were less impactful when our commercial footprint was much smaller.&#8221;
&#8220;To address current market conditions, as well as our long-term opportunity to transform the practice of premium cataract surgery, we will continue to refine our clinical education and practice adoption programs, support new customer business models, drive innovative product enhancements and advance international expansion.&#8221;
The company expects to announce the first quarter of 2025 results <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">on Wednesday, May 7, 2025</a>.
In February, RxSight reported fourth quarter adjusted EPS of $0.03, a notable improvement from $(0.13) year-over-year. Sales totaled $40.214 million, slightly <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43956479/rxsight-inc-reports-fourth-quarter-and-full-year-2024-financial-results-reaffirms-2025-guidance" rel="noreferrer noopener">missing the $40.318 million estimate</a>.
Price Action: RXST shares are down 23.9% at $19.90 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44623179" target="_blank" rel="noreferrer noopener">Larry Summers Warns Trump&#8217;s Tariffs Will Deliver &#8216;Oil Crisis-Like Shock,&#8217; Slash $30 Trillion From Economy As Markets Plunge</a></li>
</ul>
Photo via Shutterstock.

Small Cap

RXST

RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges

Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.53 by 3.77 percent. This is a 26.09 percent decrease over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $2.84 billion which missed the analyst consensus estimate of $2.90 billion by 2.03 percent. This is a 6.33 percent decrease over sales of $3.03 billion the same period last year.

Earnings Misses

Conagra Brands Q3 Adj $0.51 Misses $0.53 Estimate, Sales $2.84B Miss $2.90B Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $200 price target.

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $200 Price Target

Janney Montgomery Scott analyst John Rodis initiates coverage on Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) with a Neutral rating.

Initiation

EQBK

Janney Montgomery Scott Initiates Coverage On Equity Bancshares with Neutral Rating

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) with a Neutral and lowers the price target from $6 to $4.

KYTX

HC Wainwright & Co. Maintains Neutral on Kyverna Therapeutics, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Buy and lowers the price target from $14 to $7.

HC Wainwright & Co. Maintains Buy on Metagenomi, Lowers Price Target to $7

Canaccord Genuity analyst Richard Close initiates coverage on LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) with a Buy rating and announces Price Target of $8.

LFST

Canaccord Genuity Initiates Coverage On LifeStance Health Gr with Buy Rating, Announces Price Target of $8

Canaccord Genuity analyst Richard Close initiates coverage on Talkspace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) with a Buy rating and announces Price Target of $5.

TALK

Canaccord Genuity Initiates Coverage On Talkspace with Buy Rating, Announces Price Target of $5

Press Releases

Performance Food Group Company Completes the Acquisition of Cheney Bros, Inc.

Performance Food Group Introduces ¡Unidos! Associate Resource Group

Performance Food Group Company to Host Webcast of First-Quarter Fiscal 2025 Results

Performance Food Group Company Reports First-Quarter Fiscal 2025 Results

Performance Food Group's FarmSmart® Brand Launches Innovative Beef & Jackfruit Burger in Collaboration with The Jackfruit Company to Offer a Delicious, Healthier, and Sustainable Burger Option

Comments

Performance Food Gr

空売り

Performance Food Gr (NYSE:PFGC) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル